pharma news

News

Lilly gets back in infectious disease, via three M&A deals

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8bn.

News

Arthrosi drug trial in gout delivers for new owner Sobi

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.

News

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

News

Newel Health, Gerresheimer team up to help pharma embrace di...

Newel Health and Gerresheimer ally to help pharma firms embed digital endpoints, real-world data, and AI into clinical testing and commercialisation.

News

Gilead claims first FDA nod for a hepatitis D therapy

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

News

Late-breakers to look out for at ASCO 2026

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

Lilly gets back in infectious disease, via three M&A deals

Arthrosi drug trial in gout delivers for new owner Sobi

Datroway is first TROP2 drug for frontline breast cancer

Newel Health, Gerresheimer team up to help pharma embrace di...

Gilead claims first FDA nod for a hepatitis D therapy

Late-breakers to look out for at ASCO 2026

Trustworthy and novel AI in clinical trial planning, with Kr...

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks